Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 9540975, 13 pages
http://dx.doi.org/10.1155/2016/9540975
Research Article

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity

1Division of Translational and Experimental Oncology, Department of Medicine III, Johannes Gutenberg University, Freiligrathstrasse 12, 55131 Mainz, Germany
2BioNTech Cell & Gene Therapies GmbH, An der Goldgrube 12, 55131 Mainz, Germany
3BioNTech AG, An der Goldgrube 12, 55131 Mainz, Germany
4Ganymed Pharmaceuticals AG, An der Goldgrube 12, 55131 Mainz, Germany

Received 15 September 2015; Accepted 10 December 2015

Academic Editor: Andrew Geall

Copyright © 2016 Tana A. Omokoko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Wolchok and T. A. Chan, “Cancer: antitumour immunity gets a boost,” Nature, vol. 515, no. 7528, pp. 496–498, 2014. View at Publisher · View at Google Scholar
  2. E. G. Phimister and C. J. Melief, “Mutation-specific T cells for immunotherapy of gliomas,” The New England Journal of Medicine, vol. 372, no. 20, pp. 1956–1958, 2015. View at Publisher · View at Google Scholar
  3. M. Sznol and D. L. Longo, “Release the hounds! Activating the T-cell response to cancer,” The New England Journal of Medicine, vol. 372, no. 4, pp. 374–375, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Kreiter, M. Vormehr, N. van de Roemer et al., “Mutant MHC class II epitopes drive therapeutic immune responses to cancer,” Nature, vol. 520, no. 7549, pp. 692–696, 2015. View at Publisher · View at Google Scholar
  5. A. M. Eggermont, M. Maio, and C. Robert, “Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies,” Seminars in Oncology, vol. 42, no. 3, pp. 429–435, 2015. View at Publisher · View at Google Scholar
  6. P. Sharma and J. P. Allison, “The future of immune checkpoint therapy,” Science, vol. 348, no. 6230, pp. 56–61, 2015. View at Publisher · View at Google Scholar
  7. D. T. Le, E. Lutz, J. N. Uram et al., “Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer,” Journal of Immunotherapy, vol. 36, no. 7, pp. 382–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Rosenberg and N. P. Restifo, “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science, vol. 348, no. 6230, pp. 62–68, 2015. View at Publisher · View at Google Scholar
  9. T. Omokoko, P. Simon, Ö. Türeci, and U. Sahin, “Retrieval of functional TCRs from single antigen-specific T cells: toward individualized TCR-engineered therapies,” OncoImmunology, vol. 4, no. 7, Article ID e1005523, 2015. View at Publisher · View at Google Scholar
  10. K. T. Brunner, J. Mauel, J. C. Cerottini, and B. Chapuis, “Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs,” Immunology, vol. 14, no. 2, pp. 181–196, 1968. View at Google Scholar · View at Scopus
  11. D. S. Heo, J.-G. Park, K. Hata, R. Day, R. B. Herberman, and T. L. Whiteside, “Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity,” Cancer Research, vol. 50, no. 12, pp. 3681–3690, 1990. View at Google Scholar · View at Scopus
  12. C. Korzeniewski and D. M. Callewaert, “An enzyme-release assay for natural cytotoxicity,” Journal of Immunological Methods, vol. 64, no. 3, pp. 313–320, 1983. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Blomberg, C. Granberg, I. Hemmilä, and T. Lövgren, “Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence,” Journal of Immunological Methods, vol. 86, no. 2, pp. 225–229, 1986. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Lichtenfels, W. E. Biddison, H. Schulz, A. B. Vogt, and R. Martin, “CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity,” Journal of Immunological Methods, vol. 172, no. 2, pp. 227–239, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. M. Crouch, R. Kozlowski, K. J. Slater, and J. Fletcher, “The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity,” Journal of Immunological Methods, vol. 160, no. 1, pp. 81–88, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Karimi, E. Lee, M. H. Bachmann et al., “Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay,” PLoS ONE, vol. 9, no. 2, Article ID e89357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Schäfer, A. Schäfer, A. F. Kiderlen, K. N. Masihi, and R. Burger, “A highly sensitive cytotoxicity assay based on the release of reporter enzymes, from stably transfected cell lines,” Journal of Immunological Methods, vol. 204, no. 1, pp. 89–98, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Von Zons, P. Crowley-Nowick, D. Friberg, M. Bell, U. Koldovsky, and T. L. Whiteside, “Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 2, pp. 202–207, 1997. View at Google Scholar · View at Scopus
  19. A. R. Brasier, J. E. Tate, and J. F. Habener, “Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines,” BioTechniques, vol. 7, no. 10, pp. 1116–1122, 1989. View at Google Scholar · View at Scopus
  20. W. R. Jacobs Jr., R. G. Barletta, R. Udani et al., “Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages,” Science, vol. 260, no. 5109, pp. 819–822, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annual Review of Biomedical Engineering, vol. 4, pp. 235–260, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. C. E. Brown, C. L. Wright, A. Naranjo et al., “Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing,” Journal of Immunological Methods, vol. 297, no. 1-2, pp. 39–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. V. F. I. van Tendeloo, P. Ponsaerts, F. Lardon et al., “Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells,” Blood, vol. 98, no. 1, pp. 49–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Van Meirvenne, L. Straetman, C. Heirman et al., “Efficient genetic modification of murine dendritic cells by electroporation with mRNA,” Cancer Gene Therapy, vol. 9, no. 9, pp. 787–797, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. D. A. Mitchell and S. K. Nair, “RNA-transfected dendritic cells in cancer immunotherapy,” The Journal of Clinical Investigation, vol. 106, no. 9, pp. 1065–1069, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Kreiter, M. Diken, A. Selmi, Ö. Türeci, and U. Sahin, “Tumor vaccination using messenger RNA: prospects of a future therapy,” Current Opinion in Immunology, vol. 23, no. 3, pp. 399–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Holtkamp, S. Kreiter, A. Selmi et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells,” Blood, vol. 108, no. 13, pp. 4009–4017, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. Britten, R. G. Meyer, T. Kreer, I. Drexler, T. Wölfel, and W. Herr, “The use of HLA-A0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays,” Journal of Immunological Methods, vol. 259, no. 1-2, pp. 95–110, 2002. View at Publisher · View at Google Scholar
  29. T. Wölfel, A. van Pel, V. Brichard et al., “Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes,” European Journal of Immunology, vol. 24, no. 3, pp. 759–764, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. J. C. A. Skipper, R. C. Hendrickson, P. H. Gulden et al., “An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins,” The Journal of Experimental Medicine, vol. 183, no. 2, pp. 527–534, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Simon, T. A. Omokoko, A. Breitkreuz et al., “Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes,” Cancer Immunology Research, vol. 2, no. 12, pp. 1230–1244, 2014. View at Publisher · View at Google Scholar
  32. S. Kreiter, A. Selmi, M. Diken et al., “Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals,” Journal of Immunology, vol. 180, no. 1, pp. 309–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Jäger, Y. Nagata, S. Gnjatic et al., “Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4760–4765, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Zaritskaya, M. R. Shurin, T. J. Sayers, and A. M. Malyguine, “New flow cytometric assays for monitoring cell-mediated cytotoxicity,” Expert Review of Vaccines, vol. 9, no. 6, pp. 601–616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. B. M. Carreno, V. Magrini, M. Becker-Hapak et al., “A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells,” Science, vol. 348, no. 6236, pp. 803–808, 2015. View at Publisher · View at Google Scholar
  36. A. Gros, P. F. Robbins, X. Yao et al., “PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors,” The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2246–2259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. H. Long, W. M. Haso, J. F. Shern et al., “4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors,” Nature Medicine, vol. 21, no. 6, pp. 581–590, 2015. View at Publisher · View at Google Scholar
  38. R. Clynes, Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch, “Fc receptors are required in passive and active immunity to melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 652–656, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. J. G. van de Winkel and C. L. Anderson, “Biology of human immunoglobulin G Fc receptors,” Journal of leukocyte biology, vol. 49, no. 5, pp. 511–524, 1991. View at Google Scholar · View at Scopus
  40. O. Tuereci, S. Woell, S. Jacobs, R. Mitnacht-Kraus, and U. Sahin, “Abstract 2903. IMAB362, a novel first-in-class monoclonal antibody for treatment of pancreatic cancer,” Cancer Research, vol. 74, no. 19, supplement, p. 2903, 2014. View at Google Scholar
  41. U. Sahin, S. Al-Batran, W. Hozaeel et al., “IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): clinical activity and safety data from the PILOT phase I trial,” Journal of Clinical Oncology, vol. 33, supplement, abstract e15079, 2015. View at Google Scholar
  42. T. Trarbach, M. Schuler, Z. Zvirbule et al., “Efficacy and safety of multiple doses of IMAB362 in patients with advanced gastro-esophageal cancer: results of a phase II study,” Annals of Oncology, vol. 25, supplement 4, p. 218, 2014. View at Google Scholar
  43. M. Schuler, Z. Zvirbule, F. Lordick et al., “Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas,” Journal of Clinical Oncology, vol. 31, p. 4080, 2013. View at Google Scholar
  44. I. Hoerr, R. Obst, H.-G. Rammensee, and G. Jung, “In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies,” European Journal of Immunology, vol. 30, no. 1, pp. 1–7, 2000. View at Google Scholar · View at Scopus
  45. B. Weide, J.-P. Carralot, A. Reese et al., “Results of the first phase I/II clinical vaccination trial with direct injection of mRNA,” Journal of Immunotherapy, vol. 31, no. 2, pp. 180–188, 2008. View at Publisher · View at Google Scholar · View at Scopus